Arrowstreet Capital’s Avadel Pharmaceuticals AVDL Stock Holding History

Arrowstreet Capital’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-93,528	Closed	-$2.02M	–	1836
2025 Q4	$2.02M	Buy	+93,528	New	+$1.82M	﹤0.01%	1407
2020 Q2	–	Sell	-15,165	Closed	-$120K	–	2287
2020 Q1	$120K	Sell	15,165 -87,006	-85%	-$668K	﹤0.01%	1775
2019 Q4	$771K	Buy	+102,171	New	+$540K	﹤0.01%	1400
2018 Q3	–	Sell	-11,724	Closed	-$72K	–	1076
2018 Q2	$72K	Buy	+11,724	New	+$82.2K	﹤0.01%	1045
2017 Q4	–	Sell	-20,000	Closed	-$210K	–	1236
2017 Q3	$210K	Buy	20,000 +3,600	+22%	+$34.4K	﹤0.01%	1045
2017 Q2	$181K	Buy	+16,400	New	+$165K	﹤0.01%	1004
2014 Q4	–	Sell	-10,155	Closed	-$145K	–	1226
2014 Q3	$145K	Buy	+10,155	New	+$146K	﹤0.01%	951

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Arrowstreet Capital's AVDL Position: Q1 2026 in Review

Arrowstreet Capital sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 93,528 shares — an estimated $2.02M sold.

Arrowstreet Capital first reported a position in AVDL in Q3 2014 and held it in 7 quarters. The position peaked at $2.02M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Arrowstreet Capital reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Arrowstreet Capital sold 93,528 Avadel Pharmaceuticals shares in Q1 2026, an estimated $2.02M.
Arrowstreet Capital first reported a position in Avadel Pharmaceuticals in Q3 2014 and held it in 7 quarters.
Arrowstreet Capital's Avadel Pharmaceuticals position peaked at $2.02M in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.